期刊文献+

KGD环七肽的分子设计及性质研究 被引量:1

MOLECULAR DESIGN AND CHARACTERIZATION OF CYCLOHEPTAPEPTIDE CONTAINING THE Lys-Gly-Asp SEQUENCE
在线阅读 下载PDF
导出
摘要 通过化学合成方法合成线性长度七肽分子CKGDWDC,进而通过在(1,7)位形成二硫键构成共价闭合环状结构,最终形成KGD环七肽.结构计算结果显示,KGD环七肽中的KGD序列表现出功能构象,具有较强的抗血小板聚集活性,能够专一性识别与结合血小板膜上纤原受体,具有较强的抑制血栓形成的能力.KGD环七肽具有较强的实际应用价值和广阔的应用前景. A Linear hepta-peptide Cys-Lys-Gly-Asp-Trp-Asp-Cys was synthesized, with a disulfide bond subsequently formed between the Cysl and Cyst to obtain a cyclo-heptapeptide containing Lys-Gly-Asp. Structural simulation showed that the Lys-Gly-Asp sequence displayed functional conformation. This cycloheptapeptide exhibited potent platelet anti-aggregation activity, by specific recognition and interaction with the GP Ⅱb/Ⅲ a receptor. The peptide's specific and potent anti-thrombosis activity implicates that the cycloheptapeptide could be potentially used in the clinic.
作者 井健
出处 《北京师范大学学报(自然科学版)》 CAS CSCD 北大核心 2008年第4期417-419,共3页 Journal of Beijing Normal University(Natural Science)
基金 国家"十五"医药卫生青年基金资助项目(Z12044)
关键词 环七肽 Lys—Gly—Asp序列 血小板聚集抑制活性 纤原受体 cyclo-heptapeptide Lys-Gly-Asp sequence platelet anti-aggregation inhibitory activity GPⅡb/Ⅲ a receptor
  • 相关文献

参考文献4

  • 1Scarborough R, Rose J W, Hsu M A, et al. Barbourin. A GPIIb/IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri [J]. J Biol Chem, 1991, 566 : 9359.
  • 2Minoux H, Chipot C, Brown D, et al. Structural analysis of the KGD sequence loop of barbourin an alphaIIbbeta3-speeifie disintegrin [J]. J Comput Aided Mol Des, 2000, 14: 317.
  • 3Ellman G, Lysko H. A precise method for the determination of whole blood and plasma sulfhydryl groups[J]. Anal Biochem, 1979, 93(1) :98.
  • 4Gan Z R, Gould R J, Jacobs J W, et al. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus[J]. J Biol Chem, 1988, 263 (36):19827.

同被引文献16

  • 1Ruggeri ZM. Platelets in atherothrombosis[J].Nature Medicine,2002,(11):1227-1234.
  • 2Cachet C. Regulation of platelet functions by P2 receptors[J].Pharmacology and Toxicology,2006.277-300.
  • 3Eric J Topol,Tatiana V Byzova,Edward F Plow. Platelet GPⅡb-Ⅲa blockers[J].Lancet,1999.227-231.
  • 4Phillips DR,Charo IF,Parise LV. The platelet membrane glycoprotein Ⅱb-Ⅲa complex[J].Blood,1988.831-843.
  • 5Bennett JS. Structural biology of glycoprotein Ⅱb-Ⅲa[J].Trends in Cardiovascular Medicine,1996.31-36.
  • 6Larkin D,Murphy D,Reilly DF. A novel integrin alpha B/beta3-associated protein,functionally regulates platelet activation[J].Biological Chemistry,2004,(26):27286-27293.
  • 7Gvan Willigen,I Hers,G Gorter. Exposure of ligand-binding sites on platelet integrin alpha ⅡB/beta3 by phosphorylation of the beta3 subunit[J].Biochemical Journal,1996.769-779.
  • 8Richard SG. Platelet aggregation inhibitors for use in peripheral vascularinterventions:what CAB we learn from the experience in the eoronary arteries[J].Vasc Interv Rado1,2002,(03):229.
  • 9Jinbao Huang,Sam S,Rebello. Correlation between the in vivo efficacy of GPⅡb/Ⅲa receptor antagonists (m7E3,MK-383 and DMP-728) and exvivo platelet inhibition[J].Pharmocology,1999.252-264.
  • 10Ambresim V,Battaglia S,CioppaA. Angioplasty with stent-in-stent technique and tirofiban administration[J].J Invasive Cardid,2002.619.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部